Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan, Amlodipine and Combination in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~1. Healthy males and females~2. Aged between 18 and 45 years~3. Body weight more than 50Kg , and Body Mass Index (BMI ) between 19 and 24 kg/m2~Exclusion criteria~1. Any finding of the medical examination deviating from normal and of clinical relevance~2. Any evidence of a clinically relevant concomitant disease~3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders~4. Surgery of the gastrointestinal tract (except appendectomy)~5. Diseases of the central nervous system or psychiatric disorders or neurological disorders~6. History of relevant orthostatic hypotension, fainting spells or blackouts.~7. Chronic or relevant acute infections~8. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)~9. Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial~10. Use of drugs which might reasonably influence the results of the trial~11. Participation in another trial with an investigational drug within two months prior to administration or during the trial~12. Smoker~13. Inability to refrain from smoking during 24 hours prior to dosing and during the trial~14. Alcohol abuse or inability to stop alcoholic beverages for 24 hours prior to dosing and during the trial~15. Drug abuse~16. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)~17. Excessive physical activities (within one week prior to administration or during the trial)~18. Any laboratory value outside the reference range that is of clinical relevance~19. Inability to comply with dietary regimen of trial site~20. A history of additional risk factors for torsade de pointes~21. Any history of relevant low blood pressure~22. Supine blood pressure at screening of systolic \<110 mm Hg and diastolic \< 60 mm Hg~23. History of urticaria~24. History of angioneurotic edema 25 Pregnancy / positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion~26. No adequate contraception during the study and until 1 month of study completion 27. Lactation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- amlodipine/telmisartan/combination (Type: EXPERIMENTAL): all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order

Based on this trial design, predict the completion outcome and termination type (if applicable).